10-Q 1 clnn20230930_10q.htm FORM 10-Q clnn20230930_10q.htm
0001822791 Clene Inc. false --12-31 Q3 2023 0.0001 0.0001 300,000,000 150,000,000 128,411,981 128,411,981 74,759,591 74,759,591 20 30 3 20 30 5 5 0 0 0 0 10 10 7 10 7 5 15,000 12 12 128,411,981 74,759,591 0 0 0 0.5 20 30 0 0.5 0 0 0 0 40,000 0.1 0 5 5 00018227912023-01-012023-09-30 0001822791us-gaap:CommonStockMember2023-01-012023-09-30 0001822791us-gaap:WarrantMember2023-01-012023-09-30 xbrli:shares 00018227912023-11-03 thunderdome:item iso4217:USD 00018227912023-09-30 00018227912022-12-31 iso4217:USDxbrli:shares 0001822791us-gaap:ProductMember2023-07-012023-09-30 0001822791us-gaap:ProductMember2022-07-012022-09-30 0001822791us-gaap:ProductMember2023-01-012023-09-30 0001822791us-gaap:ProductMember2022-01-012022-09-30 0001822791us-gaap:RoyaltyMember2023-07-012023-09-30 0001822791us-gaap:RoyaltyMember2022-07-012022-09-30 0001822791us-gaap:RoyaltyMember2023-01-012023-09-30 0001822791us-gaap:RoyaltyMember2022-01-012022-09-30 00018227912023-07-012023-09-30 00018227912022-07-012022-09-30 00018227912022-01-012022-09-30 0001822791us-gaap:CommonStockMember2022-12-31 0001822791us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001822791us-gaap:RetainedEarningsMember2022-12-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001822791us-gaap:CommonStockMember2023-01-012023-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001822791us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 00018227912023-01-012023-03-31 0001822791us-gaap:CommonStockMember2023-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001822791us-gaap:RetainedEarningsMember2023-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 00018227912023-03-31 0001822791us-gaap:CommonStockMember2023-04-012023-06-30 0001822791us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001822791us-gaap:RetainedEarningsMember2023-04-012023-06-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 00018227912023-04-012023-06-30 0001822791us-gaap:CommonStockMember2023-06-30 0001822791us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001822791us-gaap:RetainedEarningsMember2023-06-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 00018227912023-06-30 0001822791us-gaap:CommonStockMember2023-07-012023-09-30 0001822791us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001822791us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001822791us-gaap:CommonStockMember2023-09-30 0001822791us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001822791us-gaap:RetainedEarningsMember2023-09-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 0001822791us-gaap:CommonStockMember2021-12-31 0001822791us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001822791us-gaap:RetainedEarningsMember2021-12-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 00018227912021-12-31 0001822791us-gaap:CommonStockMember2022-01-012022-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0001822791us-gaap:RetainedEarningsMember2022-01-012022-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-31 00018227912022-01-012022-03-31 0001822791us-gaap:CommonStockMember2022-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2022-03-31 0001822791us-gaap:RetainedEarningsMember2022-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-31 00018227912022-03-31 0001822791us-gaap:CommonStockMember2022-04-012022-06-30 0001822791us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 0001822791us-gaap:RetainedEarningsMember2022-04-012022-06-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-30 00018227912022-04-012022-06-30 0001822791us-gaap:CommonStockMember2022-06-30 0001822791us-gaap:AdditionalPaidInCapitalMember2022-06-30 0001822791us-gaap:RetainedEarningsMember2022-06-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30 00018227912022-06-30 0001822791us-gaap:CommonStockMember2022-07-012022-09-30 0001822791us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-30 0001822791us-gaap:RetainedEarningsMember2022-07-012022-09-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-30 0001822791us-gaap:CommonStockMember2022-09-30 0001822791us-gaap:AdditionalPaidInCapitalMember2022-09-30 0001822791us-gaap:RetainedEarningsMember2022-09-30 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30 00018227912022-09-30 00018227912020-12-30 utr:Y 0001822791us-gaap:EquipmentMembersrt:MinimumMember2023-09-30 0001822791us-gaap:EquipmentMembersrt:MaximumMember2023-09-30 0001822791us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-09-30 0001822791us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-09-30 0001822791us-gaap:ComputerEquipmentMembersrt:MinimumMember2023-09-30 0001822791us-gaap:ComputerEquipmentMembersrt:MaximumMember2023-09-30 0001822791clnn:ReverseRecapitalizationMemberclnn:CleneNanomedicineContingentEarnoutMember2020-12-30 utr:D 0001822791clnn:ReverseRecapitalizationMemberclnn:CleneNanomedicineContingentEarnoutMember2020-12-302020-12-30 0001822791clnn:ReverseRecapitalizationMemberclnn:InitialStockholdersContingentEarnoutMember2020-12-30 0001822791clnn:GrantFundingOnConditionalGrantsMember2023-07-012023-09-30 0001822791clnn:GrantFundingOnConditionalGrantsMember2023-01-012023-09-30 0001822791clnn:GrantFundingOnConditionalGrantsMember2022-07-012022-09-30 0001822791clnn:GrantFundingOnConditionalGrantsMember2022-01-012022-09-30 0001822791us-gaap:USTreasurySecuritiesMember2023-09-30 0001822791us-gaap:MoneyMarketFundsMember2023-09-30 0001822791us-gaap:CashEquivalentsMember2023-09-30 0001822791us-gaap:CommercialPaperMember2022-12-31 0001822791us-gaap:CorporateDebtSecuritiesMember2022-12-31 0001822791us-gaap:EquipmentMember2023-09-30 0001822791us-gaap:EquipmentMember2022-12-31 0001822791us-gaap:OfficeEquipmentMember2023-09-30 0001822791us-gaap:OfficeEquipmentMember2022-12-31 0001822791us-gaap:ComputerEquipmentMember2023-09-30 0001822791us-gaap:ComputerEquipmentMember2022-12-31 0001822791us-gaap:LeaseholdImprovementsMember2023-09-30 0001822791us-gaap:LeaseholdImprovementsMember2022-12-31 0001822791us-gaap:ConstructionInProgressMember2023-09-30 0001822791us-gaap:ConstructionInProgressMember2022-12-31 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-30 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-30 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-30 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-30 xbrli:pure 0001822791clnn:LeaseForLaboratorySpaceMember2021-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2021-09-012021-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2022-02-28 0001822791clnn:LeaseForLaboratorySpaceMember2022-02-012022-02-28 0001822791clnn:LeaseForLaboratorySpaceMember2022-01-012022-12-31 0001822791clnn:LeaseForLaboratorySpaceMember2022-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2022-09-012022-09-30 0001822791clnn:The2019CecilLoanMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2019CecilLoanMemberclnn:NotesPayableMember2022-12-31 0001822791clnn:The2019MarylandDhcdMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2019MarylandDhcdMemberclnn:NotesPayableMember2022-12-31 0001822791clnn:The2022MarylandDhcdMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2022MarylandDhcdMemberclnn:NotesPayableMember2022-12-31 0001822791clnn:AvenueMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:AvenueMemberclnn:NotesPayableMember2022-12-31 0001822791clnn:NotesPayableMember2023-09-30 0001822791clnn:NotesPayableMember2022-12-31 0001822791clnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-09-30 0001822791clnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2022-12-31 0001822791clnn:The2022DhcdLoanMemberus-gaap:ConvertibleNotesPayableMember2023-09-30 0001822791clnn:The2022DhcdLoanMemberus-gaap:ConvertibleNotesPayableMember2022-12-31 0001822791us-gaap:ConvertibleNotesPayableMember2023-09-30 0001822791us-gaap:ConvertibleNotesPayableMember2022-12-31 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2019-02-28 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2019-02-282019-02-28 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-07-012023-09-30 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-07-012022-09-30 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-09-30 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-01-012022-09-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2019-04-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2019-04-302019-04-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2023-07-012023-09-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2022-07-012022-09-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2023-01-012023-09-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2022-01-012022-09-30 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-05-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-09-30 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-05-012022-05-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-09-30 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-12-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-07-012023-09-30 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-07-012022-09-30 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-01-012022-09-30 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-12-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-09-30 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-12-012022-12-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-07-012023-09-30 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:PrimeRateMember2021-05-012021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2023-01-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2022-01-012022-12-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche1Member2021-05-012021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche1Member2021-09-012021-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche2Member2021-05-31 utr:M 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2021-05-012021-05-31 0001822791clnn:AvenueMembersrt:MinimumMemberclnn:PublicEquityOfferingMember2023-06-012023-06-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2022-12-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-07-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2022-07-012022-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-01-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2022-01-012022-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2022-01-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2023-07-012023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2022-07-012022-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2022-01-012022-09-30 0001822791clnn:WarrantsIssuedWith2021AvenueLoanMemberclnn:AvenueMember2021-05-31 0001822791clnn:NewAvenueWarrantMemberclnn:AvenueMember2023-09-30 0001822791clnn:The2019MDLoanMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2022MdLoanMemberclnn:NotesPayableMember2023-09-30 0001822791clnn:The2022DhcdLoanMemberclnn:NotesPayableMember2023-09-30 0001822791us-gaap:CapitalAdditionsMember2023-01-012023-09-30 0001822791us-gaap:CapitalAdditionsMember2022-01-012022-12-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMember2023-05-012023-05-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMembersrt:MinimumMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMembersrt:MaximumMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsAndRepairpdPhase2ClinicalTrialMembersrt:MinimumMember2023-05-012023-05-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsAndRepairpdPhase2ClinicalTrialMembersrt:MaximumMember2023-05-012023-05-31 0001822791clnn:The401kPlanMember2023-01-012023-09-30 0001822791clnn:The401kPlanMember2023-07-012023-09-30 0001822791clnn:The401kPlanMember2022-07-012022-09-30 0001822791clnn:The401kPlanMember2022-01-012022-09-30 0001822791clnn:The2014StockPlanMember2023-09-30 0001822791clnn:The2020StockPlanMember2023-09-30 0001822791clnn:The2020StockPlanMember2023-01-012023-09-30 0001822791us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0001822791us-gaap:EmployeeStockOptionMember2022-07-012022-09-30 0001822791us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0001822791us-gaap:EmployeeStockOptionMember2022-01-012022-09-30 0001822791clnn:RestrictedStockAwardsMember2023-07-012023-09-30 0001822791clnn:RestrictedStockAwardsMember2022-07-012022-09-30 0001822791clnn:RestrictedStockAwardsMember2023-01-012023-09-30 0001822791clnn:RestrictedStockAwardsMember2022-01-012022-09-30 00018227912022-01-012022-12-31 0001822791us-gaap:EmployeeStockOptionMember2023-09-30 0001822791us-gaap:EmployeeStockOptionMember2022-12-31 0001822791us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0001822791srt:MinimumMember2023-01-012023-09-30 0001822791srt:MaximumMember2023-01-012023-09-30 0001822791srt:MinimumMember2022-01-012022-09-30 0001822791srt:MaximumMember2022-01-012022-09-30 0001822791us-gaap:RestrictedStockMember2022-12-31 0001822791us-gaap:RestrictedStockMember2023-01-012023-09-30 0001822791us-gaap:RestrictedStockMember2023-09-30 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-30 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-09-30 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-09-30 0001822791us-gaap:MoneyMarketFundsMember2023-09-30 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-30 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-30 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-30 0001822791us-gaap:USTreasurySecuritiesMember2023-09-30 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel1Member2023-09-30 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel2Member2023-09-30 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-09-30 0001822791clnn:CommonStockWarrantLiabilityMember2023-09-30 0001822791us-gaap:FairValueInputsLevel1Member2023-09-30 0001822791us-gaap:FairValueInputsLevel2Member2023-09-30 0001822791us-gaap:FairValueInputsLevel3Member2023-09-30 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-31 0001822791us-gaap:MoneyMarketFundsMember2022-12-31 0001822791us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2022-12-31 0001822791us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-31 0001822791us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2022-12-31 0001822791us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-31 0001822791us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-31 0001822791us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-12-31 0001822791us-gaap:FairValueInputsLevel1Member2022-12-31 0001822791us-gaap:FairValueInputsLevel2Member2022-12-31 0001822791us-gaap:FairValueInputsLevel3Member2022-12-31 0001822791clnn:CommonStockWarrantLiabilityMember2022-12-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2022-12-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2022-12-31 0001822791clnn:CommonStockWarrantLiabilityMember2023-01-012023-09-30 0001822791clnn:CleneNanomedicineContingentEarnoutMember2023-01-012023-09-30 0001822791clnn:InitialStockholdersContingentEarnoutMember2023-01-012023-09-30 0001822791clnn:CleneNanomedicineContingentEarnoutMember2023-09-30 0001822791clnn:InitialStockholdersContingentEarnoutMember2023-09-30 0001822791clnn:CommonStockWarrantLiabilityMember2021-12-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2021-12-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2021-12-31 0001822791clnn:CommonStockWarrantLiabilityMember2022-01-012022-09-30 0001822791clnn:CleneNanomedicineContingentEarnoutMember2022-01-012022-09-30 0001822791clnn:InitialStockholdersContingentEarnoutMember2022-01-012022-09-30 0001822791clnn:CommonStockWarrantLiabilityMember2022-09-30 0001822791clnn:CleneNanomedicineContingentEarnoutMember2022-09-30 0001822791clnn:InitialStockholdersContingentEarnoutMember2022-09-30 0001822791clnn:CommonStockWarrantLiabilityMember2022-01-012022-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfChangeOfControlMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2023-09-30 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfNdaAcceptanceMember2023-09-30 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfFundamentalTransactionMember2023-09-30 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2023-09-30 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-09-30 0001822791clnn:TrancheBWarrantMemberclnn:MeasurementInputProbabilityOfNdaApprovalMember2023-09-30 0001822791clnn:TrancheBWarrantMemberclnn:MeasurementInputProbabilityOfFundamentalTransactionMember2023-09-30 0001822791clnn:TrancheBWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2023-09-30 0001822791clnn:TrancheBWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2023-09-30 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputPriceVolatilityMember2023-09-30 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-09-30 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-30 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedTermMember2023-09-30 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedTermMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020OneMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnDecember2020OneMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020TwoMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnDecember2020TwoMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020ThreeMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnDecember2020ThreeMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnMay2021Member2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnMay2021Member2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023OneMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnJune2023OneMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023TwoMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnJune2023TwoMember2022-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023ThreeMember2023-09-30 0001822791clnn:CommonStockWarrantExercisableOnJune2023ThreeMember2022-12-31 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2020-12-30 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2020-12-302020-12-30 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2023-01-012023-09-30 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2022-01-012022-12-31 0001822791clnn:ChardanUnitPurchaseOptionMember2020-12-30 0001822791clnn:ChardanUnitPurchaseOptionMember2023-01-012023-09-30 0001822791clnn:ChardanUnitPurchaseOptionMember2022-01-012022-12-31 0001822791clnn:WarrantsOriginallyIssuedByCleneNanomedicineMember2020-12-30 0001822791clnn:WarrantsWithTranche2Of2021AvenueLoanMember2021-05-31 0001822791clnn:WarrantsWithTranche2Of2021AvenueLoanMember2023-01-012023-09-30 0001822791clnn:NewAvenueWarrantMember2023-06-30 0001822791clnn:NewAvenueWarrantMember2023-01-012023-09-30 0001822791clnn:TrancheAWarrantMember2023-06-30 0001822791clnn:TrancheAWarrantMember2023-01-012023-09-30 0001822791clnn:TrancheBWarrantMember2023-06-30 0001822791clnn:TrancheBWarrantMember2023-01-012023-09-30 0001822791clnn:OfferingAgreementMember2022-10-012022-10-31 0001822791clnn:OfferingAgreementMember2022-10-31 0001822791clnn:CanaccordMemberclnn:UnderwritingAgreementMember2023-06-012023-06-30 0001822791clnn:CanaccordMemberclnn:UnderwritingAgreementMember2023-06-30 0001822791clnn:TrancheAWarrantMemberclnn:CanaccordMember2023-06-30 0001822791clnn:TrancheBWarrantMemberclnn:CanaccordMember2023-06-30 0001822791clnn:AtmFacilityMember2022-04-142022-04-14 0001822791clnn:AtmFacilityMember2023-01-012023-09-30 0001822791clnn:AtmFacilityMember2023-07-012023-09-30 0001822791clnn:AtmFacilityMember2022-01-012022-09-30 0001822791clnn:AtmFacilityMember2022-07-012022-09-30 0001822791clnn:LincolnParkCapitalFundLlcMembersrt:MaximumMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2023-03-032023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMembersrt:MinimumMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2023-09-30 0001822791clnn:LincolnParkMemberclnn:PurchaseAgreementMember2023-01-012023-09-30 0001822791clnn:LincolnParkMemberclnn:CommitmentSharesMemberclnn:PurchaseAgreementMember2023-01-012023-09-30 0001822791clnn:LincolnParkMemberclnn:PurchaseAgreementMember2023-07-012023-09-30 0001822791us-gaap:ConvertibleNotesPayableMember2023-07-012023-09-30 0001822791us-gaap:ConvertibleNotesPayableMember2022-07-012022-09-30 0001822791us-gaap:ConvertibleNotesPayableMember2023-01-012023-09-30 0001822791us-gaap:ConvertibleNotesPayableMember2022-01-012022-09-30 0001822791clnn:CommonStockWarrantsMember2023-07-012023-09-30 0001822791clnn:CommonStockWarrantsMember2022-07-012022-09-30 0001822791clnn:CommonStockWarrantsMember2023-01-012023-09-30 0001822791clnn:CommonStockWarrantsMember2022-01-012022-09-30 0001822791us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0001822791us-gaap:EmployeeStockOptionMember2022-07-012022-09-30 0001822791us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0001822791us-gaap:EmployeeStockOptionMember2022-01-012022-09-30 0001822791us-gaap:RestrictedStockMember2023-07-012023-09-30 0001822791us-gaap:RestrictedStockMember2022-07-012022-09-30 0001822791us-gaap:RestrictedStockMember2023-01-012023-09-30 0001822791us-gaap:RestrictedStockMember2022-01-012022-09-30 0001822791clnn:ContingentEarnoutSharesMember2023-07-012023-09-30 0001822791clnn:ContingentEarnoutSharesMember2022-07-012022-09-30 0001822791clnn:ContingentEarnoutSharesMember2023-01-012023-09-30 0001822791clnn:ContingentEarnoutSharesMember2022-01-012022-09-30 0001822791clnn:SupplyAgreementMemberclnn:FourLifeMember2018-08-012018-08-31 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2023-07-012023-09-30 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2022-07-012022-09-30 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2023-01-012023-09-30 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2022-01-012022-09-30 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2023-07-012023-09-30 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2022-07-012022-09-30 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2023-01-012023-09-30 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2022-01-012022-09-30 0001822791us-gaap:RelatedPartyMember2023-07-012023-09-30 0001822791us-gaap:RelatedPartyMember2022-07-012022-09-30 0001822791us-gaap:RelatedPartyMember2023-01-012023-09-30 0001822791us-gaap:RelatedPartyMember2022-01-012022-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2023-07-012023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2022-07-012022-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2023-01-012023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2022-01-012022-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2023-07-012023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2022-07-012022-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2023-01-012023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2022-01-012022-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:DrugsSegmentMember2022-12-31 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2023-09-30 0001822791us-gaap:OperatingSegmentsMemberclnn:SupplementsSegmentMember2022-12-31 0001822791us-gaap:CorporateNonSegmentMember2023-09-30 0001822791us-gaap:CorporateNonSegmentMember2022-12-31
 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 01-39834


CLENE INC.

(Exact name of registrant as specified in its charter)


 

Delaware

 

85-2828339

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

6550 South Millrock Drive, Suite G50

Salt Lake City, Utah

 

84121

(Address of principal executive offices)

 

(Zip Code)

 

 (801) 676 9695 

(Registrant’s telephone number, including area code)

 N/A 

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value

 

CLNN

 

The Nasdaq Capital Market

Warrants, to acquire one-half of one share of Common Stock for $11.50 per share

 

CLNNW

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

  

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

The number of shares outstanding of the Registrant’s common stock as of November 3, 2023 was 128,415,605.

 
 

CLENE INC.

Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2023

 

PART IFINANCIAL INFORMATION

1

 

Item 1.

Financial Statements (Unaudited)

1

   

Condensed Consolidated Balance Sheets

1
   

Condensed Consolidated Statements of Operations and Comprehensive Loss

2
   

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

3

   

Condensed Consolidated Statements of Cash Flows

4

   

Notes to Condensed Consolidated Financial Statements

5

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

36

 

Item 4.

Controls and Procedures

36

       

PART IIOTHER INFORMATION

38

 

Item 1.

Legal Proceedings

38

 

Item 1A.

Risk Factors

38

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

39

 

Item 3.

Defaults Upon Senior Securities

39

 

Item 4.

Mine Safety Disclosures

39

 

Item 5.

Other Information

39

 

Item 6.

Exhibits

39

 

 
 

PART IFINANCIAL INFORMATION

 

Item 1. Financial Statements

 

CLENE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

  

September 30,

  

December 31,

 
  

2023

  

2022

 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $42,113  $18,332 

Marketable securities

     4,983 

Accounts receivable

  64   189 

Inventory

  104   43 

Prepaid expenses and other current assets

  4,165   5,648 

Total current assets

  46,446   29,195 

Restricted cash

  58   58 

Operating lease right-of-use assets

  4,287   4,602 

Property and equipment, net

  9,642   10,638 

TOTAL ASSETS

 $60,433  $44,493 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        

Accounts payable

 $1,889  $3,014 

Accrued liabilities

  3,194   3,863 

Operating lease obligations, current portion

  553   488 

Finance lease obligations, current portion

  44   74 

Notes payable, current portion

  9,588   6,418 

Total current liabilities

  15,268   13,857 

Operating lease obligations, net of current portion

  5,080   5,557 

Finance lease obligations, net of current portion

     34 

Notes payable, net of current portion

  6,675   9,483 

Convertible notes payable

  9,975   9,770 

Common stock warrant liabilities

  1,860    

Clene Nanomedicine contingent earn-out liability

  150   2,264 

Initial Stockholders contingent earn-out liability

  19   291 

TOTAL LIABILITIES

  39,027   41,256 

Commitments and contingencies (Note 9)

          

Stockholders’ equity:

        

Common stock, $0.0001 par value: 300,000,000 and 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 128,411,981 and 74,759,591 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively

  13   7 

Additional paid-in capital

  253,854   196,246 

Accumulated deficit

  (232,550)  (193,219)

Accumulated other comprehensive income

  89   203 

TOTAL STOCKHOLDERS’ EQUITY

  21,406   3,237 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $60,433  $44,493 

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2023

   

2022

   

2023

   

2022

 

Revenue:

                               

Product revenue

  $ 65     $ 130     $ 355     $ 139  

Royalty revenue

    43       44       129       100  

Total revenue

    108       174       484       239  

Operating expenses:

                               

Cost of revenue

    12       19       83       19  

Research and development

    5,972       6,403       19,982       24,149  

General and administrative

    3,666       3,557       11,029       12,807  

Total operating expenses

    9,650       9,979       31,094       36,975  

Loss from operations

    (9,542 )     (9,805 )     (30,610 )     (36,736 )

Other income (expense), net:

                               

Interest income

    546       59       931       144  

Interest expense

    (1,188 )     (857 )     (3,358 )     (2,390 )

Gain on termination of lease

                      420  

Commitment share expense

                (402 )      

Issuance costs for common stock warrant liability

                (333 )      

Loss on initial issuance of equity

                (14,840 )      

Change in fair value of common stock warrant liabilities

    6,341       149       5,958       151  

Change in fair value of Clene Nanomedicine contingent earn-out liability

    1,004       (1,591 )     2,114       6,662  

Change in fair value of Initial Stockholders contingent earn-out liability

    129       (205 )     272       849  

Research and development tax credits and unrestricted grants

    247       1,346       902       2,001  

Other income (expense), net

    45       (72 )     35       35  

Total other income (expense), net

    7,124       (1,171 )     (8,721 )     7,872  

Net loss before income taxes

    (2,418 )     (10,976 )     (39,331 )     (28,864 )

Income tax benefit

                       

Net loss

    (2,418 )     (10,976 )     (39,331 )     (28,864 )
                                 

Other comprehensive loss:

                               

Unrealized gain (loss) on available-for-sale securities

    (4 )     33       16       (54 )

Foreign currency translation adjustments

    (81 )     (39 )     (130 )     (99 )

Total other comprehensive loss

    (85 )     (6 )     (114 )     (153 )

Comprehensive loss

  $ (2,503 )   $ (10,982 )   $ (39,445 )   $ (29,017 )
                                 

Net loss per share – basic and diluted

  $ (0.02 )   $ (0.17 )   $ (0.41 )   $ (0.46 )

Weighted average common shares used to compute basic and diluted net loss per share

    128,405,483       63,508,928       97,026,964       63,234,757  

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)

 

   

Common Stock

   

Additional Paid-In

   

Accumulated

   

Accumulated Other Comprehensive

   

Total Stockholders’

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Income (Loss)

   

Equity (Deficit)

 

Balances at December 31, 2022

    74,759,591     $ 7     $ 196,246     $ (193,219 )   $ 203     $ 3,237  

Issuance of common stock

    3,227,758       1       4,664                   4,665  

Stock-based compensation expense

                2,223                   2,223  

Unrealized gain on available-for-sale securities

                            14       14  

Foreign currency translation adjustment

                            4       4  

Net loss

                      (11,770 )           (11,770 )

Balances at March 31, 2023

    77,987,349     $ 8     $ 203,133     $ (204,989 )   $ 221     $ (1,627 )

Issuance of common stock

    50,402,893       5       40,924                   40,929  

Issuance of equity-classified warrants

                4,970                   4,970  

Stock-based compensation expense

                2,451                   2,451  

Issuance of common stock upon vesting of restricted stock awards

    10,870                                

Unrealized gain on available-for-sale securities

                            6       6  

Foreign currency translation adjustment

                            (53 )     (53 )

Net loss

                      (25,143 )           (25,143 )

Balances at June 30, 2023

    128,401,112     $ 13     $ 251,478     $ (230,132 )   $ 174     $ 21,533  

Common stock issuance costs

                (20 )                 (20 )

Stock-based compensation expense

                2,396                   2,396  

Issuance of common stock upon vesting of restricted stock awards

    10,869                                

Unrealized loss on available-for-sale securities

                            (4 )     (4 )

Foreign currency translation adjustment

                            (81 )     (81 )

Net loss

                      (2,418 )           (2,418 )

Balances at September 30, 2023

    128,411,981     $ 13     $ 253,854     $ (232,550 )   $ 89     $ 21,406  
                                                 

Balances at December 31, 2021

    62,312,097       6       175,659       (163,301 )     233       12,597  

Reclassification of common stock warrant liability to equity

                305                   305  

Exercise of stock options

    934,448             267                   267  

Stock-based compensation expense

                2,202                   2,202  

Unrealized loss on available-for-sale securities

                            (50 )     (50 )

Foreign currency translation adjustment

                            50       50  

Net loss

                      (13,354 )           (13,354 )

Balances at March 31, 2022

    63,246,545     $ 6     $ 178,433     $ (176,655 )   $ 233     $ 2,017  

Exercise of stock options

    110,000             17                   17  

Stock-based compensation expense

                2,184                   2,184  

Issuance of common stock upon vesting of restricted stock awards

    65,363                                

Unrealized loss on available-for-sale securities

                            (37 )     (37 )

Offering costs

                (100 )                 (100 )

Foreign currency translation adjustment

                            (110 )     (110 )

Net loss

                      (4,534 )           (4,534 )

Balances at June 30, 2022

    63,421,908     $ 6     $ 180,534     $ (181,189 )   $ 86     $ (563 )

Issuance of common stock, net of issuance costs

    40,000             128                   128  

Stock-based compensation expense

                2,098                   2,098  

Issuance of common stock upon vesting of restricted stock awards

    80,076                                

Unrealized gain on available-for-sale securities

                            33       33  

Foreign currency translation adjustment

                            (39 )     (39 )

Net loss

                      (10,976 )           (10,976 )

Balances at September 30, 2022

    63,541,984     $ 6     $ 182,760     $ (192,165 )   $ 80     $ (9,319 )

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

   

Nine Months Ended September 30,

 
   

2023

   

2022

 

Cash flows from operating activities:

               

Net loss

  $ (39,331 )   $ (28,864 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation

    1,283       715  

Non-cash lease expense

    315       285  

Commitment share expense

    402        

Issuance costs for common stock warrant liability

    333        

Loss on initial issuance of equity

    14,840        

Change in fair value of common stock warrant liabilities

    (5,958 )     (151 )

Change in fair value of Clene Nanomedicine contingent earn-out liability

    (2,114 )     (6,662 )

Change in fair value of Initial Stockholders contingent earn-out liability

    (272 )     (849 )

Stock-based compensation expense

    7,070       6,484  

Gain on termination of lease

          (420 )

Loss on sale of marketable securities

          2  

Accretion of debt discount

    819       661  

Non-cash interest expense

    273       83  

Changes in operating assets and liabilities:

               

Accounts receivable

    125       (77 )

Inventory

    (61 )     3  

Prepaid expenses and other current assets

    1,483       (884 )

Accounts payable

    (1,125 )     213  

Accrued liabilities

    (669 )     (1,474 )

Operating lease obligations

    (412 )     (360 )

Net cash used in operating activities

    (22,999 )     (31,295 )

Cash flows from investing activities:

               

Purchases of marketable securities

          (24,582 )

Proceeds from maturities of marketable securities

    5,000       8,000  

Proceeds from sales of marketable securities

          7,614  

Purchases of property and equipment

    (287 )     (3,478 )

Net cash provided by (used in) investing activities

    4,713       (12,446 )

Cash flows from financing activities:

               

Proceeds from exercise of stock options

          284  

Proceeds from at-the-market offering

          132  

Payments of at-the-market offering commissions

          (4 )

Proceeds from issuance of common stock and warrants, net of offering costs

    42,094        

Payments of finance lease obligations

    (63 )     (101 )

Proceeds from the issuance of notes payable

    350       694  

Payments of notes payable issuance costs

          (30 )

Payments of notes payable modification fees

    (200 )      

Payment of deferred offering costs

          (100 )

Net cash provided by financing activities

    42,181       875  

Effect of foreign exchange rate changes on cash and restricted cash

    (114 )     (155 )

Net increase (decrease) in cash, cash equivalents and restricted cash

    23,781       (43,021 )

Cash, cash equivalents and restricted cash – beginning of period

    18,390       50,346  

Cash, cash equivalents and restricted cash – end of period

  $ 42,171     $ 7,325  
                 

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets

               

Cash and cash equivalents

    42,113       7,267  

Restricted cash

    58       58  

Cash, cash equivalents and restricted cash

  $ 42,171     $ 7,325  
                 

Supplemental disclosure of non-cash investing and financing activities:

               

Common stock warrant liability recorded upon debt modification

  $ 692     $  

Common stock warrant liability recorded upon public stock offering

  $ 7,126     $  

Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives

  $     $ 2,343  

Lease incentive realized

  $     $ 500  

Lease liability settled through termination of lease

  $     $ 602  

Reclassification of common stock warrant liability to permanent equity

  $     $ 305  

Purchases of property and equipment in accounts payable

  $     $ 1,318  

Supplemental cash flow information:

               

Cash paid for interest expense

  $ 2,266     $ 1,646  

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1. Nature of the Business

 

Clene Inc. (the “Company,” “we,” “us,” or similar such references) is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform which enables production of concentrated, stable, highly active, clean-surfaced nanocrystal suspensions. We have multiple drug assets currently in development for applications primarily in neurology. Our efforts are currently focused on addressing the high unmet medical needs in central nervous system disorders including Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”). Our patented electro-crystal-chemistry manufacturing platform further enables us to develop very low concentration dietary supplements to advance the health and well-being of broad populations. These dietary supplements can vary greatly and include nanocrystals of varying composition, shapes and sizes as well as ionic solutions with diverse metallic constituents. Dietary supplements are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc., or through an exclusive license with 4Life Research LLC (“4Life”), a related party (see Note 15).

 

Clene Nanomedicine, Inc. (“Clene Nanomedicine”) became a public company on December 30, 2020 (the “Closing Date”) when it completed a reverse recapitalization (the “Reverse Recapitalization”) with Tottenham Acquisition I Limited (“Tottenham”), Tottenham’s wholly-owned subsidiary and our predecessor, Chelsea Worldwide Inc., and Creative Worldwide Inc., a wholly-owned subsidiary of Chelsea Worldwide Inc. On the Closing Date, Chelsea Worldwide Inc. changed its name to Clene Inc. and listed its shares of common stock, par value $0.0001 per share (“Common Stock”) on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLNN.”

 

Going Concern

 

We incurred a loss from operations of $9.5 million and $9.8 million for the three months ended September 30, 2023 and 2022, respectively; and $30.6 million and $36.7 million for the nine months ended September 30, 2023 and 2022, respectively. Our accumulated deficit was $232.6 million and $193.2 million as of September 30, 2023 and December 31, 2022, respectively. Our cash, cash equivalents, and marketable securities totaled $42.1 million and $23.3 million as of September 30, 2023 and December 31, 2022, respectively, and net cash used in operating activities was $23.0 million and $31.3 million for the nine months ended September 30, 2023 and 2022, respectively.

 

We have incurred significant losses and negative cash flows from operations since our inception. We have not generated significant revenues since our inception, and we do not anticipate generating significant revenues unless we successfully complete development and obtain regulatory approval for commercialization of a drug candidate. We expect to incur additional losses in the future, particularly as we advance the development of our clinical-stage drug candidates, continue research and development of our preclinical drug candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. We expect that within the next twelve months, we will not have sufficient cash and other resources on hand to sustain our current operations or meet our obligations as they become due unless we obtain additional financing. Additionally, pursuant to our term loan with Avenue Venture Opportunities Fund, L.P. (“Avenue”), we are required to maintain unrestricted cash and cash equivalents of at least $5.0 million to avoid acceleration of the full balance of the loan (see Note 8). These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility and equity purchase agreement and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. We have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts and elimination of certain staff positions. We have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.

 

The accompanying condensed consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As a result, the accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

 

5

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of Clene Inc. and our wholly-owned subsidiaries, Clene Nanomedicine, Inc., a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (“Clene Australia”), a subsidiary incorporated in Australia, Clene Netherlands B.V. (“Clene Netherlands”), a subsidiary incorporated in the Netherlands, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions. We have prepared the accompanying condensed consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The financial data and other information disclosed in the condensed consolidated financial statements and related notes for the three and nine months ended September 30, 2023 and 2022 are unaudited.

 

Results of operations for the three and nine months ended September 30, 2023 and 2022 are not necessarily indicative of the results for the entire fiscal year or any other period. The condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022 should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.

 

Risks and Uncertainties

 

We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial condition, results of operations, or cash flows: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of third-party contract research organizations (“CROs”) and manufacturers upon which we rely; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract and retain employees necessary to support our growth. The product candidates we develop require approvals from regulatory agencies prior to commercial sales. There can be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial statements.

 

The extent of the impact of the COVID-19 pandemic, including the resurgence of cases relating to the spread of new variants, on our business and operations is highly uncertain. While the COVID-19 pandemic has led to various research restrictions and led to pauses and early conclusion of one of our clinical trials, these impacts have been temporary and to date we have not experienced material business disruptions or incurred impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic. We are not aware of any specific related event or circumstance that would require us to revise the estimates reflected in our condensed consolidated financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, financial condition, results of operations, and cash flows, including planned future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects.

 

Concentrations of Credit Risk

 

Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

 

Cash and Cash Equivalents

 

We consider all short-term investments with original maturities of 90 days or less when purchased to be cash equivalents.

 

Restricted Cash

 

We classify cash as restricted when it is unavailable for withdrawal or use in our general operating activities. Restricted cash is classified as current and noncurrent on the condensed consolidated balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related to our corporate credit card.

 

6

 

Marketable Securities

 

Marketable securities are investments with original maturities of more than 90 days when purchased. We do not invest in securities with original maturities of more than one year. Marketable debt securities are considered available-for-sale, and are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income until realized. Realized gains and losses are included in other income (expense), net, on the basis of specific identification. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in other income (expense), net.

 

Inventory

 

Inventory is stated at historic cost on a first-in first-out basis. Our inventory consisted of $72,000 in raw materials and $32,000 in finished goods as of September 30, 2023, and $29,000 in raw material and $14,000 in finished goods as of December 31, 2022. Inventory relates to our Supplements segment.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment, computer software, and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5 years for laboratory equipment, 3-7 years for furniture and fixtures, and 2-5 years for computer software. Leasehold improvements are amortized over the lesser of the estimated lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.

 

We capitalize costs to obtain or develop computer software for internal use, including development costs incurred during the software development stage and costs to obtain software for access and conversion of historical data. We also capitalize costs to modify, upgrade, or enhance existing internal-use software that result in additional functionality. We expense costs incurred during the preliminary project stage, training costs, data conversion costs, and maintenance costs.

 

Debt

 

When debt is issued and a derivative is required to be separated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g., warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance costs related to debt are recorded as deductions that net against the principal value of the debt and are amortized to interest expense over the contractual term of the debt using the effective interest method.

 

Convertible Debt

 

In accordance with ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, when we issue notes with conversion features, we evaluate if the conversion feature is freestanding or embedded. If the conversion feature is embedded, we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its historical cost, as long as no other features require separation and recognition as derivatives. If the conversion feature is freestanding, or is embedded and meets the requirements to be separated, we account for the conversion feature as a derivative under ASC 815, Derivatives and Hedging (“ASC 815”). We record the derivative instrument at fair value at inception, and subsequently re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes recorded in the condensed consolidated statements of operations and comprehensive loss.

 

7

 

Leases

 

At inception of a contract, we determine if a contract meets the definition of a lease. We determine if the contract conveys the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both of the following: (i) the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing rate is used as the discount rate. Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets and we recognize lease expense for these short-term leases on a straight-line basis over the lease term.

 

Certain lease agreements may require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.

 

Leases may contain clauses for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. Operating lease expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are included in research and development or general and administrative expenses consistent with the leased assets’ primary use. Accretion on the liabilities for finance leases is included in interest expense.

 

Contingent Earn-Out Liabilities

 

In connection with the Reverse Recapitalization, certain Clene Nanomedicine stockholders are entitled to receive additional shares of Common Stock (the “Clene Nanomedicine Contingent Earn-out”) as follows: (i) 3,338,483 shares if (a) the volume-weighted average price (“VWAP”) of our Common Stock equals or exceeds $15.00 (the “Milestone 1 Price”) in any twenty trading days within a thirty trading day period within three years of the Reverse Recapitalization or (b) the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within three years of the closing of the Reverse Recapitalization (the requirements in (a) and (b) collectively, “Milestone 1”); (ii) 2,503,851 shares if (a) the VWAP of our Common Stock equals or exceeds $20.00 (the “Milestone 2 Price”) in any twenty trading days within a thirty trading day period within five years of the closing of the Reverse Recapitalization or (b) the change of control price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within five years of the Reverse Recapitalization (the requirements in (a) and (b) collectively, “Milestone 2”). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene Nanomedicine stockholders will receive additional shares equal to Milestone 1. Tottenham’s former officers, directors, sponsor, and public stockholders (the “Initial Stockholders”) are entitled to receive earn-out shares (the “Initial Stockholders Contingent Earn-out,” and collectively with the Clene Nanomedicine Contingent Earn-out, the “Contingent Earn-outs”) as follows: (i) 375,000 shares upon the achievement of Milestone 1; and (ii) 375,000 shares upon achievement of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Stockholders will receive additional shares equal to Milestone 1.

 

In accordance with ASC 815, the Contingent Earn-outs are not indexed to our own stock and therefore were accounted for as a liability at the Reverse Recapitalization date and are subsequently remeasured to fair value at each reporting date with changes recorded as a component of other income (expense), net.

 

Common Stock Warrants

 

We account for common stock warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.

 

8

 

Grant Funding

 

We may submit applications to receive grant funding from governmental and non-governmental entities. We account for grants by analogizing to the grant accounting model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). We recognize grant funding without conditions or continuing performance obligations, including certain research and development tax credits, as other income in the condensed consolidated statements of operations and comprehensive loss. We accrue certain research and development tax credits receivable in other current assets (see Note 4) in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage and we recognize other income in the condensed consolidated statements of operations and comprehensive loss. After submission of our tax returns, we receive a cash refund of certain research and development tax credits and relieve the receivable.

 

We recognize grant funding with conditions or continuing performance obligations as a reduction in research and development expenses in the period during which the related qualifying expenses are incurred and as the conditions or performance obligations are fulfilled. Any amount received in advance of fulfilling such conditions or performance obligations is recorded in accrued liabilities (see Note 6) if the conditions or performance obligations are expected to be met within the next twelve months. We recognized grant funding of $0.2 million and $0.3 million as a reduction of research and development expenses during the three and nine months ended September 30, 2023, respectively. We did not fulfill any grant conditions or performance obligations during the three and nine months ended September 30, 2022.

 

Foreign Currency Translation and Transactions

 

Our functional currency is the U.S. dollar. Clene Australia determined its functional currency to be the Australian dollar and Clene Netherlands determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and stockholders’ equity is translated using historical rates. Adjustments resulting from the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of stockholders’ equity. We also incur foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included in other income (expense), net, as incurred.

 

Comprehensive Loss

 

Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The only elements of other comprehensive loss in any periods presented were translation of foreign currency denominated balances of Clene Australia and Clene Netherlands to U.S. dollars for consolidation and unrealized gain (loss) on available-for-sale securities.

 

Segment Information

 

We have determined that our chief executive officer is the chief operating decision maker (“CODM”). Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding resource allocation and assessing performance. We view our operations and manage our business in two operating segments, which are our reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (“Drugs”), and (2) the development and commercialization of dietary supplements (“Supplements”).

 

Income Taxes

 

We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

 

We account for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, which are considered appropriate as well as the related net interest and penalties.

 

9

 

Stock-Based Compensation

 

We account for stock-based compensation arrangements using a fair value-based method for costs related to all share-based payments including stock options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses based on the classification of the work performed by the grantees. The fair value is recognized over the period during which a grantee is required to provide services in exchange for the option award and service-based stock awards, known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions, the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied. We recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related service period had been completed in a prior period. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures. We determine the fair value of each share of Common Stock underlying stock-based awards using a Black-Scholes option pricing model based on the closing price of our Common Stock as reported by Nasdaq on the date of grant. The fair value of stock awards with market conditions are determined using a Monte Carlo valuation model.

 

Note 3. Cash, Cash Equivalents, and Marketable Securities

 

Available-for-Sale Securities

 

Available-for-sale securities as of September 30, 2023, which had contractual maturities within 90 days and were classified within cash equivalents in the condensed consolidated balance sheets, were as follows:

 

  

September 30, 2023

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized Gains

  

Gross Unrealized Losses

  

Fair Value

 

U.S. Treasury securities

 $24,163  $1  $  $24,164 

Money market funds

  14,058         14,058 

Total

 $38,221  $1  $  $38,222 

 

Available-for-sale securities as of  December 31, 2022, which had contractual maturities within one year, were as follows:

 

  

December 31, 2022

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized
Gains

  

Gross Unrealized
Losses

  

Fair Value

 

Commercial paper

 $3,496  $  $(14) $3,482 

Corporate debt securities

  1,501         1,501 

Total

 $4,997  $  $(14) $4,983 

 

Proceeds from the sale and maturity of marketable securities held as available-for-sale were as follows:

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 

(in thousands)

 

2023

  

2022

  

2023

  

2022

 

Proceeds from maturities of marketable securities

 $  $5,500  $5,000  $8,000 

Proceeds from sales of marketable securities

     4,597      7,614 

Total

 $  $10,097  $5,000  $15,614 

 

Realized gains and losses included in earnings from the sale of available-for-sale securities were insignificant. As of September 30, 2023 and December 31, 2022, we did not have any allowance for credit losses or impairments of available-for-sale securities.

 

Note 4. Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets as of September 30, 2023 and December 31, 2022 were as follows:

 

   

September 30,

   

December 31,

 

(in thousands)

 

2023

   

2022

 

Research and development tax credits receivable

  $ 1,084     $ 2,777  

Metals to be used in research and development

    2,052       2,290  

Other

    1,029       581  

Total prepaid expenses and other current assets

  $ 4,165     $ 5,648  

 

10

 

Note 5. Property and Equipment, Net

 

Property and equipment, net, as of September 30, 2023 and December 31, 2022 were as follows:

 

   

September 30,

   

December 31,

 

(in thousands)

 

2023

   

2022

 

Lab equipment

  $ 4,135     $ 3,934  

Office equipment

    178       177  

Computer software

    459       459  

Leasehold improvements

    9,983       5,677  

Construction in progress

    1,406       5,664  
      16,161       15,911  

Less accumulated depreciation

    (6,519 )     (5,273 )

Total property and equipment, net

  $ 9,642     $ 10,638  

 

Depreciation expense recorded in research and development expense and general and administrative expense for the three and nine months ended September 30, 2023 and 2022 was as follows:

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 

(in thousands)

 

2023

   

2022

   

2023

   

2022

 

General and administrative

  $ 66     $ 67     $ 200     $ 163  

Research and development

    373       166       1,083       552  

Total depreciation expense

  $ 439     $ 233     $ 1,283     $ 715  
 

Note 6. Accrued Liabilities

 

Accrued liabilities as of September 30, 2023 and December 31, 2022 were as follows:

 

   

September 30,

   

December 31,

 

(in thousands)

 

2023

   

2022

 

Accrued compensation and benefits

  $ 1,507     $ 2,007  

Accrued CRO and clinical fees

    1,154       1,297  

Other

    533       559  

Total accrued liabilities

  $ 3,194     $ 3,863  
 

Note 7. Leases

 

We lease laboratory and office space and certain laboratory equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases. We expect that, in the normal course of business, the existing leases will be renewed or replaced by similar leases.

 

Operating Leases

 

Operating leases primarily consist of real estate leases for office and laboratory space. We have three real estate leases: (i) a laboratory and manufacturing facility which commenced in September 2021 with a ten-year term and an option to extend for two five-year periods; (ii) a laboratory and manufacturing facility which commenced in February 2022 with a seven-year term and an option to extend for two five-year periods, which replaced a previous lease for the same facility and resulted a gain on termination of $0.4 million for the year ended December 31, 2022; and (iii) our corporate office which commenced a renewed term in September 2022 for seven years with an option to extend for five years. We did not recognize the payments to be made in the option periods as part of the right-of-use asset or lease liability because the exercise of the option is not reasonably certain.

 

As of September 30, 2023 and December 31, 2022, our operating lease obligations had a weighted-average discount rate of 9.6% and 9.6%, respectively; and a weighted-average remaining term of 6.6 years and 7.3 years, respectively.

 

11

 

Finance Leases

 

Assets recorded under finance lease obligations and included in property and equipment as of September 30, 2023 and December 31, 2022 were as follows:

 

   

September 30,

   

December 31,

 

(in thousands)

 

2023

   

2022

 

Lab equipment

  $ 408     $ 408  

Work in process

    228       228  

Total

    636       636  

Less accumulated depreciation

    (383 )     (326 )

Net

  $ 253     $ 310  

 

As of September 30, 2023 and December 31, 2022, our finance lease obligations had a weighted-average interest rate of 10.9% and 10.2%, respectively; and a weighted-average remaining term of 0.6 years and 1.2 years, respectively.

 

Maturity Analysis of Lease Obligations

 

The maturity analysis of our finance and operating lease obligations as of September 30, 2023 was as follows:

 

(in thousands)

 

Finance Leases

   

Operating Leases

 

2023 (remainder)

  $ 19     $ 194  

2024

    27       1,178  

2025

          1,208  

2026

          1,236  

2027

          1,132  

2028

          1,093  

Thereafter

          1,694  

Total minimum lease payments

    46       7,735  

Less amount representing interest/discounting

    (2 )     (2,102 )

Present value of minimum lease payments

    44       5,633  

Less lease obligations, current portion

    (44 )     (553 )

Lease obligations, net of current portion

  $     $ 5,080  

 

Components of Lease Cost

 

The components of finance and operating lease costs for the three and nine months ended September 30, 2023 and 2022 were as follows:

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 

(in thousands)

 

2023

   

2022

   

2023

   

2022

 

Finance lease costs:

                               

Amortization

  $ 16     $ 20     $ 57     $ 61  

Interest on lease liabilities

    1       6       10       12  

Operating lease costs

    254       256       758       695  

Short-term lease costs

    1             3        

Variable lease costs

    70       65       192       238  

Total lease costs

  $ 3